rheumatic%20fever%20-%20acute
RHEUMATIC FEVER - ACUTE
Acute rheumatic fever is an autoimmune response to a previous group A beta-hemolytic streptococcal (GAS) infection causing acute generalized anti-inflammatory response primarily affecting the heart.
It often presents in patients 5-14 years of age and uncommon before 3 years and after 21 years of age.
Patients presenting with acute rheumatic fever are severely unwell, in extreme pain and requires hospitalization.

Rheumatic Fever - Acute Drug Information

Drug Information

Indication: Relief of mild to moderate pain & fever.

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: Upper & lower resp tract infections, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicat...

Indication: HTN. Adjunct to digitalis &/or diuretic therapy in CHF.

Actimol Menstrual
pamabrom + paracetamol

Indication: Symptomatic relief of bloating, water-wt gain, backache, muscular aches, pre-menstrual & menstrual discomf...

Alka-Seltzer
aspirin + citric acid + sodium bicarbonate

Indication: Relief of headache & upset stomach. Fever, colds & flu discomfort, muscular aches & pains.

Indication: Upper & lower resp tract, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicated gonococc...

Indication: Infections due to gm -ve & +ve organisms & non-penicillinase-producing staph.

1  /  22
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.